NEURO61

Session information

Print

Symposium

[S-48] Symposium 48
State-of-the-art basic research for Alzheimer's disease

Wed. Sep 2, 2020 9:00 AM - 10:30 AM Room 12 (Okayama International Center 8F event Hall)

Chair：MakotoHiguchi（National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology）,AtsushiIwata（Department of Neurology, Tokyo Metropolitan Geriatric Medical Center Hospital）

[S-48-1] Uncovering molecular etiology of dementia through nonclinical developments of therapeutics

○Makoto Higuchi (National Institutes for Quantum and Radiological Science and Technology, Japan)

In recent years, many clinical trials for Alzheimer's disease (AD) have ended in disappointment. Now it's time to rethink strategy to defeat AD. In this symposium, researchers at the vanguard of AD basic research will introduce their recent remarkable work, including elucidation of AD pathomechanisms, generation of AD animal models, and establishing new concepts of therapies and biomarkers utilizing cutting-edge technologies. We believe that talk in this session will provide neurologists important insights to gain a better understanding of AD.

[S-48-2] Propagation of pathogenic proteins and therapeutic intervention in Alzheimer's disease

○Takeshi Iwatsubo (Neuropathology, The University of Tokyo, Japan)

In recent years, many clinical trials for Alzheimer's disease (AD) have ended in disappointment. Now it's time to rethink strategy to defeat AD. In this symposium, researchers at the vanguard of AD basic research will introduce their recent remarkable work, including elucidation of AD pathomechanisms, generation of AD animal models, and establishing new concepts of therapies and biomarkers utilizing cutting-edge technologies. We believe that talk in this session will provide neurologists important insights to gain a better understanding of AD.

[S-48-3] Generation of Alzheimer's disease animal models - from mice to non-human primates

○Hiroki Sasaguri1,2 (1.Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Japan, 2.Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan)

In recent years, many clinical trials for Alzheimer's disease (AD) have ended in disappointment. Now it's time to rethink strategy to defeat AD. In this symposium, researchers at the vanguard of AD basic research will introduce their recent remarkable work, including elucidation of AD pathomechanisms, generation of AD animal models, and establishing new concepts of therapies and biomarkers utilizing cutting-edge technologies. We believe that talk in this session will provide neurologists important insights to gain a better understanding of AD.

[S-48-4] Genomic integrity in Alzheimer's disease

○Tatsuo Mano (Department of Neurology, The University of Tokyo, Japan)

In recent years, many clinical trials for Alzheimer's disease (AD) have ended in disappointment. Now it's time to rethink strategy to defeat AD. In this symposium, researchers at the vanguard of AD basic research will introduce their recent remarkable work, including elucidation of AD pathomechanisms, generation of AD animal models, and establishing new concepts of therapies and biomarkers utilizing cutting-edge technologies. We believe that talk in this session will provide neurologists important insights to gain a better understanding of AD.

[S-48-5] Progression of Alzheimer's disease, tau propagation, and tau-targeting therapies

○Shuko Takeda (Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Japan)

In recent years, many clinical trials for Alzheimer's disease (AD) have ended in disappointment. Now it's time to rethink strategy to defeat AD. In this symposium, researchers at the vanguard of AD basic research will introduce their recent remarkable work, including elucidation of AD pathomechanisms, generation of AD animal models, and establishing new concepts of therapies and biomarkers utilizing cutting-edge technologies. We believe that talk in this session will provide neurologists important insights to gain a better understanding of AD.